The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:36 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #44. PDL BioPharma Type 2 diabetes products licensed by Depomed

Acquirer: PDL BioPharma (PDLI)
Acquiree: Type 2 diabetes products licensed by Depomed (DEPO)
Details: PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash payment. PDL will receive all royalty and milestone payments due under the agreements until it has received payments equal to two times the cash payment made to Depomed, after which all payments received will be shared evenly between PDL and Depomed.

PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.

Open the PDLI Page at The Online Investor »

PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.

Open the DEPO Page at The Online Investor »

Company Name: 
PDL BioPharma Inc
Stock buyback: 
PDLI buyback
Website: 
www.pdl.com
Sector: 
Rental, Leasing, & Royalty
Number of ETFs Holding PDLI: 
10
Total Market Value Held by ETFs: 
$12.34M
Total Market Capitalization: 
$310.00M
% of Market Cap. Held by ETFs: 
3.98%
Company Name: 
Assertio Therapeutics Inc
Website: 
www.depomed.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes


Biotechnology M&A - Slide 44 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.